This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.
product summary
company name :
Enzo Life Sciences
other brands :
Stressgen, BioMol, Alexis Corporation, Assay Designs, Alexis
product type :
chemical
product name :
Bicalutamide
catalog :
ALX-270-476-M100
quantity :
100 mg
citations: 10
Reference |
---|
Rivero J, Luzardo O, HenrÃquez Hernández L, MachÃn R, Pestano J, Zumbado M, et al. In vitro evaluation of oestrogenic/androgenic activity of the serum organochlorine pesticide mixtures previously described in a breast cancer case-control study. Sci Total Environ. 2015;537:197-202 pubmed publisher
|
Ko S, Shi L, Kim S, Song C, Chatterjee B. Interplay of nuclear factor-kappaB and B-myb in the negative regulation of androgen receptor expression by tumor necrosis factor alpha. Mol Endocrinol. 2008;22:273-86 pubmed
|
Dehm S, Tindall D. Androgen receptor structural and functional elements: role and regulation in prostate cancer. Mol Endocrinol. 2007;21:2855-63 pubmed
|
Cinar B, Mukhopadhyay N, Meng G, Freeman M. Phosphoinositide 3-kinase-independent non-genomic signals transit from the androgen receptor to Akt1 in membrane raft microdomains. J Biol Chem. 2007;282:29584-93 pubmed
|
Mitterberger M, Neuwirt H, Cavarretta I, Hobisch A, Culig Z. Increased resistance to trail-induced apoptosis in prostate cancer cells selected in the presence of bicalutamide. Prostate. 2007;67:1194-201 pubmed
|
Guo J, Jiang C, Wang Z, Lee H, Hu H, Malewicz B, et al. A novel class of pyranocoumarin anti-androgen receptor signaling compounds. Mol Cancer Ther. 2007;6:907-17 pubmed
|
Srinivasan S, Ranga R, Burikhanov R, Han S, Chendil D. Par-4-dependent apoptosis by the dietary compound withaferin A in prostate cancer cells. Cancer Res. 2007;67:246-53 pubmed
|
Burd C, Morey L, Knudsen K. Androgen receptor corepressors and prostate cancer. Endocr Relat Cancer. 2006;13:979-94 pubmed
|
Castilla C, Congregado B, Chinchón D, Torrubia F, Japon M, Saez C. Bcl-xL is overexpressed in hormone-resistant prostate cancer and promotes survival of LNCaP cells via interaction with proapoptotic Bak. Endocrinology. 2006;147:4960-7 pubmed
|
Mimeault M, Batra S. Recent advances on multiple tumorigenic cascades involved in prostatic cancer progression and targeting therapies. Carcinogenesis. 2006;27:1-22 pubmed
|
product information
Product ID :
ALX-270-476
Catalog Number :
ALX-270-476-M100
Product Name :
Bicalutamide
Product Type :
Biochemical
Size :
100 mg
list of Pubmed id :
26282753, 17975021, 17636035, 17635910, 17520660, 17363485, 17185378, 17158750, 16794010, 16195239
Product Description :
Nonsteroidal antiandrogen. Effective in the treatment of prostate cancer. Induces cell death by a pathway that is independent of changes in mitochondrial membrane potential and Bcl-2 action.
ALTnames :
N-(4-Cyano-3-(trifluoromethyl)phenyl)-3-((4-fluorophenyl)sulfonyl)-2-hydroxy-2-methylpropanamide
Purity :
≥98% (HPLC)
Storage :
-20°C
company information
Enzo Life Sciences
5777 Hines Drive
Ann Arbor, MI 48108
Ann Arbor, MI 48108
info-us@enzolifesciences.
https://www.enzolifesciences.com1-800-942-0430
headquarters: USA
Enzo Life Sciences, incorporating ALEXIS® Biochemicals and BIOMOL® International, offers a comprehensive panel of innovative life science reagents. Antibodies, enzymes, proteins, small molecule inhibitors, product libraries, and assay kits are available for research in Cancer, Cell Death, Epigenetics, Genomics, Immunology, Neuroscience, Signal Transduction, and Ubiquitin & Proteasomes, Enabling Discovery in Life Science(tm). Visit www.enzolifesciences.com.
questions and comments